Huberman LabPeptides: The Science, Uses & Safety | Dr. Abud Bakri
Episode Details
EPISODE INFO
- Released
- June 1, 2026
- Duration
- 2h 48m
- Channel
- Huberman Lab
- Watch on YouTube
- ▶ Open ↗
EPISODE DESCRIPTION
Dr. Abud Bakri, MD, is a board-certified internal medicine physician and expert in the science and clinical use of peptides. We discuss the history, uses, sourcing and safety of BPC-157, GHK-Cu, pinealon, epithalon, GLP-1s, retatrutide, melanotan and growth hormone-promoting peptides. We discuss the gap that exists between animal and human data and meaningful differences in the sources for different peptides. For those interested in peptides, Dr. Bakri provides a grounded look at the science, risks and uncertainties shaping the field today. Show notes: https://go.hubermanlab.com/LKUoSIM Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://eightsleep.com/huberman Lingo: https://hellolingo.com/huberman Function: https://functionhealth.com/huberman LMNT: https://drinklmnt.com/huberman Huberman Lab Instagram: https://www.instagram.com/hubermanlab Threads: https://www.threads.net/@hubermanlab X: https://x.com/hubermanlab Facebook: https://www.facebook.com/hubermanlab TikTok: https://www.tiktok.com/@hubermanlab LinkedIn: https://www.linkedin.com/in/andrew-huberman Website: https://www.hubermanlab.com Newsletter: https://www.hubermanlab.com/newsletter Dr. Abud Bakri Website: https://abudbakri.com Substack: https://abud.substack.com X: https://x.com/AbudBakri Instagram: https://www.instagram.com/Abud_Bakri Threads: https://www.threads.com/@abud_bakri LinkedIn: https://www.linkedin.com/in/abud-bakri-md-a3975a193 YouTube: https://www.youtube.com/@AbudBakri Timestamps 00:00:00 Abud Bakri 00:03:33 What are Peptides?, Receptors 00:06:26 BPC-157, Discovery, Animal Proteins 00:11:19 BPC-157, Animal Data, Regeneration 00:12:27 Sponsors: Eight Sleep & Lingo 00:14:51 BPC-157, Regeneration & Healing, Neurological Effects 00:19:27 Adverse Events, Clinical Trials & Legality of BPC-157 00:29:41 GLPs & Compounding Pharmacy; Peptides & Gray Market 00:35:25 Manufacturing, Compounding Pharmacies, Gray Market, Black Market 00:41:32 Peptides & Tumor Growth?; Angiogenesis 00:45:17 Sponsor: AG1 00:47:01 Pharmaceutical Patents, Clinical Trials for BPC-157, Potential Outcomes 00:54:19 BPC-157 Healing, Patient Experiences 01:01:22 Physician Counsel, FDA Legality, Malpractice 01:07:25 Pinealon, Epithalon, Discovery; Sleep & Cognitive Performance, Risks 01:18:17 Sponsor: Function 01:19:55 Pineal Age Deterioration, Epithalon, Eye Health 01:29:38 Thymus, Age Shrinkage; Thymosin Alpha-1, Immune Function 01:38:13 TB-500; Pet Health; Thymic Peptide Doses, Thymulin, Zinc 01:49:13 Sponsor: LMNT 01:50:33 GHK-Cu (Copper GHK), Collagen 01:55:32 Illness Recovery, Thymic Score, Tool: Blood Test & Immune Cell Counts 02:04:01 Growth Hormone Secretagogues, Age Decline, Cancer Risk, Insulin 02:15:36 GHK-Cu, Topical Cream, Red Light Therapy 02:20:25 GLPs, Discovery, Physical & Cognitive Long-Term Effects, Fertility 02:33:53 Retatrutide; Drug Patents & Nomenclature 02:39:03 Peptides: Women Reproductive Disorders; TBI, Neurologic Effect; Safe Sources 02:45:34 Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter #hubermanlab #science #health #peptides Disclaimer & Disclosures: https://www.hubermanlab.com/disclaimer
SPEAKERS
Dr. Abud Bakri
guestPhysician and peptide/GLP-1 clinician who discusses peptide science, safety, and clinical use including work in a VA clinic.
Andrew Huberman
hostProfessor of neurobiology and ophthalmology at Stanford School of Medicine and host of the Huberman Lab podcast.
EPISODE SUMMARY
In this episode of Huberman Lab, featuring Dr. Abud Bakri and Andrew Huberman, Peptides: The Science, Uses & Safety | Dr. Abud Bakri explores peptides explained: mechanisms, safety, sourcing, and real-world clinical controversies Peptides are framed as a core biological “language,” best categorized by whether they have known receptors (e.g., GLP-1 agonists) versus unclear/unknown targets (e.g., BPC-157, TB-500), which strongly affects confidence in mechanism and safety.
RELATED EPISODES